Profile
| Metric | Value |
|---|---|
| Full Name | Aktis Oncology, Inc. |
| Ticker | NASDAQ: AKTS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | aktisoncology.com |
| Employees | - |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $19.64 | |
| Price, 1D Change | -4.20% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 3.98 | |
| Revenue | - | |
| Revenue, 1Y Change | - | |
| EPS | $0.00 | |
| EPS, 1Y Change | 0.00% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | N/A | |
| Last Ann. Earnings | N/A | |
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | DNLX | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.00 | |
| EPS Estimate | - | |
| EPS Est. Change | - | |
| Revenue | - | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $19.64 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.83 | N/A | - | |
| - | N/A | - | |
| - | N/A | - | |
| - | N/A | - |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $27.23M | N/A | - | |
| $27.38M | N/A | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | - | |
| Price, 3Y | - | |
| Market Cap, 1Y | - | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | - | |
| Revenue, 3Y | - | |
| EPS, 1Y | 0.00% | |
| EPS, 3Y | - |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $19.64 | |
| SMA 200 | $20.92 | |
| SMA 200 vs Price | +6.50% | |
| SMA 50 | $20.92 | |
| SMA 50 vs Price | +6.50% | |
| Beta | 3.98 | |
| ATR | $1.56 | |
| 14-Day RSI | 35.99 | |
| 10-Day Volatility | 84.44% | |
| 1-Year Volatility | 74.49% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| - | ||
| Payout Ratio | - |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | - | |
| EPS | $0.00 | |
| Gross Profit | $0.00 | |
| Gross Margin | - | |
| Operating Profit | - | |
| Operating Margin | - | |
| Net Income | - | |
| Net Margin | - | |
| EBITDA | - |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | - | |
| Current Ratio | - | |
| Quick Ratio | - | |
| Interest Coverage | - | |
| F-Score | - | |
| - |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | -7.79 | |
| EV/EBITDA | - | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | - | |
| Cash & Equivalents | $297.17M | |
| Total Assets | - | |
| Current Assets | - | |
| Total Liabilities | - | |
| Current Liabilities | - | |
| Total Debt | $0.00 | |
| Short Term Debt | - | |
| Accounts Payable | - |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | - | |
| Operating Expenses | - | |
| Cost Of Goods Sold | - | |
| SG&A | $12.58M | |
| D&A | - | |
| Interest Expense | $0.00 | |
| Income Tax | - |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | - | |
| CFI | - | |
| CFF | - | |
| Capex | - | |
| Free Cash Flow | - |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Piper Sandler | → | |
| Oppenheimer | → | |
| B. Riley Securities | → | |
| Roth MKM | ||
| Oppenheimer | ||
| B. Riley Securities | ||
| Oppenheimer | ||
| Piper Sandler | ||
| Piper Sandler | ||
| Oppenheimer |
Analyst sentiment
Institutional ownership
Screeners with AKTS
FAQ
What is the ticker symbol for Aktis Oncology, Inc.?
The ticker symbol for Aktis Oncology, Inc. is NASDAQ:AKTS
Does Aktis Oncology, Inc. pay dividends?
No, Aktis Oncology, Inc. does not pay dividends
What sector is Aktis Oncology, Inc. in?
Aktis Oncology, Inc. is in the Healthcare sector
What industry is Aktis Oncology, Inc. in?
Aktis Oncology, Inc. is in the Biotechnology industry
What country is Aktis Oncology, Inc. based in?
Aktis Oncology, Inc. is headquartered in United States
When did Aktis Oncology, Inc. go public?
Aktis Oncology, Inc. initial public offering (IPO) was on January 9, 2026
Is Aktis Oncology, Inc. in the S&P 500?
No, Aktis Oncology, Inc. is not included in the S&P 500 index
Is Aktis Oncology, Inc. in the NASDAQ 100?
No, Aktis Oncology, Inc. is not included in the NASDAQ 100 index
Is Aktis Oncology, Inc. in the Dow Jones?
No, Aktis Oncology, Inc. is not included in the Dow Jones index
When does Aktis Oncology, Inc. report earnings?
The next expected earnings date for Aktis Oncology, Inc. is February 27, 2026
Data Sources & References
- AKTS Official Website www.aktisoncology.com
- AKTS Profile on Yahoo Finance finance.yahoo.com/quote/AKTS
- AKTS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/akts